CN114832052A - Traditional Chinese medicine composition for treating benign prostatic hyperplasia - Google Patents

Traditional Chinese medicine composition for treating benign prostatic hyperplasia Download PDF

Info

Publication number
CN114832052A
CN114832052A CN202210508707.8A CN202210508707A CN114832052A CN 114832052 A CN114832052 A CN 114832052A CN 202210508707 A CN202210508707 A CN 202210508707A CN 114832052 A CN114832052 A CN 114832052A
Authority
CN
China
Prior art keywords
chinese medicine
traditional chinese
benign prostatic
prostatic hyperplasia
seed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202210508707.8A
Other languages
Chinese (zh)
Other versions
CN114832052B (en
Inventor
孙建明
毛剑敏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Seventh Peoples Hospital
Original Assignee
Shanghai Seventh Peoples Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Seventh Peoples Hospital filed Critical Shanghai Seventh Peoples Hospital
Priority to CN202210508707.8A priority Critical patent/CN114832052B/en
Publication of CN114832052A publication Critical patent/CN114832052A/en
Application granted granted Critical
Publication of CN114832052B publication Critical patent/CN114832052B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/286—Carthamus (distaff thistle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/288—Taraxacum (dandelion)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/84—Valerianaceae (Valerian family), e.g. valerian
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention discloses a traditional Chinese medicine composition for treating benign prostatic hyperplasia, which consists of the following components: 10g of muskroot-like semiaquilegia root, 15g of cowherb seed, 10g of peach kernel, 6g of safflower, 10g of eupatorium fortunei, 15g of herba patriniae, 15g of medicinal cyathula root, 10g of herba lycopi, 15g of polygonum aviculare, 15g of polyporus umbellatus, 3g of ricepaperplant pith, 10g of fenugreek seed, 3g of cinnamon, 6g of ephedra, 10g of white mustard seed and 15g of dandelion; the prescription mainly adopts herbaceous plants, achieves the effects of inducing diuresis for treating stranguria, reducing swelling, resolving masses, tonifying kidney and promoting qi circulation by scientific and reasonable compatibility, thereby achieving the purpose of treating benign prostatic hyperplasia, and has remarkable clinical effect, satisfaction of patients and no obvious side effect.

Description

Traditional Chinese medicine composition for treating benign prostatic hyperplasia
Technical Field
The invention belongs to the technical field of traditional Chinese medicine formulas, and particularly relates to a traditional Chinese medicine composition for treating benign prostatic hyperplasia.
Background
Benign prostatic hyperplasia mainly causes urination disorders of middle-aged and old men, and clinically takes symptoms of urine waiting, urinary line thinning, intermittent urination, nocturia increasing, dribbling after urination and the like as main manifestations, and severe patients can also have acute urine retention; the western medicine treatment mostly adopts a mode of orally taking a 5 alpha reductase inhibitor and an alpha receptor blocker, wherein the 5 alpha reductase inhibitor has the hidden danger of reducing the libido of the male and causing sexual dysfunction, and the alpha receptor blocker has the risk of causing hypotension of the patient.
Therefore, a pure traditional Chinese medicine compound composition with good treatment effect on benign prostatic hyperplasia is needed, and the side effect on a human body in the treatment process is reduced to the maximum extent.
Disclosure of Invention
In order to solve the technical problems, the invention provides a traditional Chinese medicine composition for treating benign prostatic hyperplasia, which mainly adopts herbaceous plants to achieve the effects of inducing diuresis for treating stranguria, relieving swelling, resolving masses, tonifying kidney and promoting qi circulation, thereby playing a role in treating benign prostatic hyperplasia;
in order to achieve the technical purpose, the invention is realized by the following technical scheme that the traditional Chinese medicine composition for treating benign prostatic hyperplasia comprises the following components:
8-15 g of muskroot-like semiaquilegia root, 10-20 g of cowherb seed, 8-15 g of peach seed, 5-10 g of safflower, 8-15 g of eupatorium fortunei, 10-20 g of herba patriniae, 10-20 g of medicinal cyathula root, 8-15 g of herba lycopi, 10-20 g of polygonum aviculare, 10-20 g of polyporus, 1-5 g of ricepaper pith, 8-15 g of fenugreek, 1-5 g of cinnamon, 5-10 g of ephedra, 8-15 g of white mustard seed and 10-20 g of dandelion;
preferably, the traditional Chinese medicine composition comprises 10g of muskroot-like semiaquilegia root, 15g of cowherb seed, 10g of peach kernel, 6g of safflower, 10g of eupatorium, 15g of herba patriniae, 15g of medicinal cyathula root, 10g of herba lycopi, 15g of polygonum aviculare, 15g of polyporus, 3g of ricepaperplant pith, 10g of fenugreek, 3g of cinnamon, 6g of ephedra herb, 10g of white mustard seed and 15g of dandelion;
another object of the present invention is to provide a method for using a Chinese medicinal composition for treating benign prostatic hyperplasia, which comprises the following steps:
s1: soaking the traditional Chinese medicine raw materials provided by the invention in clear water for 20 minutes, removing the soaking water, putting the raw materials into an earthen pot, adding water which is 10 times of the raw materials to submerge the raw materials of the medicinal materials for 2-3cm, boiling the raw materials with strong fire, then decocting the raw materials with slow fire for 30min, and filtering the decoction to obtain a first liquid medicine;
s2: adding 8 times of water into the residue, decocting for 15min, and filtering to obtain the second filtrate;
s3: mixing the filtrates, and administering 1 time in the morning and evening each day.
The pharmacological and medicinal properties of the raw materials of the medicine related by the invention are as follows:
muskroot-like semiaquilegia root: is cold in nature, slightly bitter and slightly pungent in taste, and has the effects of clearing away heat and toxic materials, relieving swelling, resolving hard mass, inducing diuresis and treating stranguria;
dandelion: is cold in nature, bitter and sweet in taste, enters liver and stomach channels, and has the effects of clearing away heat and toxic materials, resolving carbuncle and resolving hard mass, inducing diuresis for treating stranguria, clearing liver and improving eyesight;
fenugreek: warm in nature, bitter in taste, entering liver and kidney meridians, and has effects of warming kidney, tonifying yang, dispelling cold and relieving pain;
seed of cowherb: the medicine has mild nature and bitter taste, enters liver and stomach channels, and has the effects of activating blood circulation to promote menstruation, promoting lactation to eliminate carbuncle, inducing diuresis and treating stranguria;
radix cyathulae: neutral in nature, sweet and bitter in taste, such as liver and kidney meridians, and has the effects of promoting blood circulation, stimulating the menstrual flow, dispelling pathogenic wind, removing dampness, easing joint movement, inducing diuresis and treating stranguria;
peach kernel: the product has mild property, sweet and bitter taste, and has effects of anticoagulation and hemostasis after entering heart, liver and large intestine channels;
safflower: warm in nature, pungent in flavor, enter heart and liver meridians, and have effects of promoting blood circulation and removing blood stasis;
herba Eupatorii: has mild nature and pungent taste, enters spleen, stomach and lung channels, and has effects of eliminating dampness and relieving summer-heat;
herba Patriniae: has mild property and bitter taste, and has the effects of clearing away heat and toxic materials, expelling pus and eliminating nodules;
herba lycopi: warm in nature, pungent and bitter in flavor, entering liver and spleen meridians, and having the effects of promoting diuresis, relieving swelling, removing toxic substance and resolving carbuncle;
herba polygoni avicularis: is cold in nature and bitter in taste, enters bladder channels, and has the effects of promoting diuresis, treating stranguria, killing parasites and relieving itching;
and (3) polyporus umbellatus: the product has mild nature and sweet taste, enters kidney and bladder channels, and has the effects of inducing diuresis and treating stranguria;
ricepaperplant pith: cold in nature, sweet and bland in flavor, enters lung and stomach meridians, and has the effects of relieving swelling and treating stranguria;
cinnamon: being hot in nature, pungent and sweet in flavor, entering kidney, spleen, heart and liver channels, and having the effects of tonifying fire, supporting yang, guiding fire to the source, dispelling cold, relieving pain, promoting blood circulation and dredging channels;
herba ephedrae: warm in nature, pungent and bitter in flavor, entering lung and bladder meridians, and has the effects of inducing diuresis and relieving swelling;
white mustard seed: warm in nature and pungent in flavor, enter lung, and have the effects of warming lung, resolving fluid retention, promoting qi circulation, resolving hard mass, dredging collaterals and relieving pain.
The invention has the beneficial effects that:
the formula mainly adopts herbaceous plants, achieves the effects of inducing diuresis for treating stranguria, relieving swelling, removing stasis, tonifying kidney and promoting qi circulation by scientific and reasonable compatibility of medicines, thereby achieving the aim of treating benign prostatic hyperplasia, and has remarkable clinical effect, satisfaction of patients and no obvious side effect; the prescription not only has the functions of treating stranguria by diuresis, reducing swelling and resolving masses, but also has the function of tonifying the kidney, and clinical observation shows that the prescription has the effect of shrinking prostate.
Detailed Description
The technical solutions in the embodiments of the present invention are clearly and completely described, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
A Chinese medicinal composition for treating benign prostatic hyperplasia comprises the following components: 10g of muskroot-like semiaquilegia root, 15g of cowherb seed, 10g of peach kernel, 6g of safflower, 10g of eupatorium fortunei, 15g of herba patriniae, 15g of medicinal cyathula root, 10g of herba lycopi, 15g of polygonum aviculare, 15g of polyporus umbellatus, 3g of ricepaperplant pith, 10g of fenugreek seed, 3g of cinnamon, 6g of ephedra, 10g of white mustard seed and 15g of dandelion.
Example 2
Clinical statistics of cases
1) Case subjects: clinically observing patients with benign prostatic hyperplasia, damp heat and blood stasis, wherein the IPSS score is 8-35, 68 cases exist, the patients are 45-80 years old, the disease onset time is 11-351 months, 2 cases are removed, 1 case is removed, and 65 cases are observed;
2) symptom and curative effect evaluation criteria: the clinical curative effect of the patient is evaluated by adopting a traditional Chinese medicine syndrome grading and quantitative integral table, international prostate symptom score, life quality score, serum prostate specific antigen level, prostate ultrasonic examination, maximum uroflow rate examination and residual urine volume of bladder;
3) the medicine taking mode is as follows: the traditional Chinese medicine composition provided in the embodiment 1, namely the traditional Chinese medicine decoction of the 'lan ling tong ze decoction' (the taking method is 1 bag each time, the traditional Chinese medicine decoction is taken 0.5 hour after meal and is taken 2 times a day), and the traditional Chinese medicine decoction is combined with oral selective alpha at the same time 1 The receptor retarder doxazosin mesylate sustained release tablet (administration method is 4mg each time, oral administration 0.5 hours after meal, 1 time daily). Specific Chinese medicine and its garmentThe application method comprises the following steps:
4) the curative effect results are as follows: the effective rate is 20 percent and the significant efficiency is 64.62 percent in 65 cases after the treatment course is finished;
and (3) counting the curative effect index: the Chinese medicine symptom curative effect evaluation standard (according to the Chinese medicine new drug clinical research guideline) is that the curative effect index is (pre-treatment integral-post-treatment integral) ÷ pre-treatment integral multiplied by 100%;
clinical relief: before and after administration, symptoms and physical signs are obviously improved (the curative effect index is more than or equal to 95 percent);
secondly, effect is displayed: after the medicine is taken, the symptoms and physical signs are obviously improved (the curative effect index is more than or equal to 70 percent and less than 95 percent);
③ effective: after the medicine is taken, symptoms and signs are improved (the curative effect index is more than or equal to 30 percent and less than 70 percent);
fourthly, invalidation: those with no significant reduction or worsening of symptoms and signs after administration (efficacy index < 30%);
5) the symptoms before and after treatment of the patient are scored according to the international prostate symptom (IPSS) score and the quality of life (QoL) score which are currently internationally recognized as the best means for judging the severity of the symptoms of the patient with benign prostatic hyperplasia, and the symptom curative effect index is calculated.
Firstly, curing: the symptom degree score is reduced by more than or equal to 90 percent compared with the score before treatment
Secondly, effect is displayed: the symptom degree score is reduced by more than or equal to 60 percent and less than 90 percent compared with the score before treatment
③ effective: the symptom degree score is reduced by more than or equal to 30 percent and less than 60 percent compared with the score before treatment
Fourthly, invalidation: symptom severity score was less than 30% less than before treatment
Note: score of symptom degree: [ (before treatment integration-after treatment integration) ÷ before treatment integration ] × 100%
The total effective is curing + obvious effect + effective.
And (5) counting results: in 65 cases, 3 cases were substantially cured, 42 cases were significantly improved, 13 cases were improved, and 7 cases were unchanged.
Analysis of results
1) Comparison in group:
after 12 weeks of treatment and during follow-up visit of two groups of patients, the traditional Chinese medicine syndrome grading quantitative score chart, IPSS and QoL scores are lower than those before treatment, and the difference has statistical significance.
2) Comparison between groups:
before treatment, the two groups of traditional Chinese medicine syndrome grading and quantitative integral tables, IPSS and QoL scores, serum prostate specific antigen levels, prostate ultrasonic examination, maximum uroflow rate examination and residual urine volume of bladder have no statistical difference; after 12 weeks of treatment and at follow-up visit, the two groups of traditional Chinese medicine syndrome grading quantitative integral tables, IPSS and QoL scores and the difference of serum prostate specific antigen levels have statistical significance.
3) The treatment group is better than the control group in the aspects of improving BPH symptoms and delaying the disease progression of patients.
In the description herein, references to the description of "one embodiment," "an example," "a specific example" or the like are intended to mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above do not necessarily refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.
The preferred embodiments of the invention disclosed above are intended to be illustrative only. The preferred embodiments are not intended to be exhaustive or to limit the invention to the precise embodiments disclosed. Obviously, many modifications and variations are possible in light of the above teaching. The embodiments were chosen and described in order to best explain the principles of the invention and the practical application, to thereby enable others skilled in the art to best utilize the invention. The invention is limited only by the claims and their full scope and equivalents.

Claims (3)

1. A traditional Chinese medicine composition for treating benign prostatic hyperplasia is characterized by comprising the following components: 8-15 g of muskroot-like semiaquilegia root, 10-20 g of cowherb seed, 8-15 g of peach seed, 5-10 g of safflower, 8-15 g of eupatorium fortunei, 10-20 g of herba patriniae, 10-20 g of medicinal cyathula root, 8-15 g of herba lycopi, 10-20 g of polygonum aviculare, 10-20 g of polyporus, 1-5 g of ricepaper pith, 8-15 g of fenugreek, 1-5 g of cinnamon, 5-10 g of ephedra, 8-15 g of white mustard seed and 10-20 g of dandelion.
2. The traditional Chinese medicine composition for treating benign prostatic hyperplasia according to claim 1, wherein the traditional Chinese medicine composition comprises 10g of muskroot-like semiaquilegia root, 15g of cowherb seed, 10g of peach kernel, 6g of safflower, 10g of eupatorium fortunei, 15g of herba patriniae, 15g of medicinal cyathula root, 10g of herba lycopi, 15g of polygonum aviculare, 15g of polyporus umbellatus, 3g of ricepaperplant pith, 10g of fenugreek, 3g of cinnamon, 6g of ephedra herb, 10g of white mustard seed and 15g of dandelion.
3. A use method of a traditional Chinese medicine composition for treating benign prostatic hyperplasia is characterized by comprising the following steps:
s1: soaking the traditional Chinese medicine raw materials provided by the invention in clear water for 20 minutes, removing the soaking water, putting the raw materials into an earthen pot, adding water which is 10 times of the raw materials to submerge the raw materials of the medicinal materials for 2-3cm, boiling the raw materials with strong fire, then decocting the raw materials with slow fire for 30min, and filtering the decoction to obtain a first liquid medicine;
s2: adding 8 times of water into the residue, decocting for 15min, and filtering to obtain the second filtrate;
s3: mixing the filtrates, and administering 1 time in the morning and evening each day.
CN202210508707.8A 2022-05-10 2022-05-10 Traditional Chinese medicine composition for treating benign prostatic hyperplasia Active CN114832052B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210508707.8A CN114832052B (en) 2022-05-10 2022-05-10 Traditional Chinese medicine composition for treating benign prostatic hyperplasia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210508707.8A CN114832052B (en) 2022-05-10 2022-05-10 Traditional Chinese medicine composition for treating benign prostatic hyperplasia

Publications (2)

Publication Number Publication Date
CN114832052A true CN114832052A (en) 2022-08-02
CN114832052B CN114832052B (en) 2023-09-05

Family

ID=82568821

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210508707.8A Active CN114832052B (en) 2022-05-10 2022-05-10 Traditional Chinese medicine composition for treating benign prostatic hyperplasia

Country Status (1)

Country Link
CN (1) CN114832052B (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107412404A (en) * 2017-07-26 2017-12-01 四川易创生物科技有限公司 A kind of Chinese medicine composition for treating bladder prostate proliferation of blood stasis blocking disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107412404A (en) * 2017-07-26 2017-12-01 四川易创生物科技有限公司 A kind of Chinese medicine composition for treating bladder prostate proliferation of blood stasis blocking disease

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
常通玮,李俊岭: "补肾活血利水汤治疗前列腺增生症70例", vol. 6, no. 02, pages 128 - 129 *
桂泽红,陈志强,王树声,白遵光,傅岳武,张策: "补肾活血散结汤治疗良性前列腺增生症的疗效观察" *
桂泽红,陈志强,王树声,白遵光,傅岳武,张策: "补肾活血散结汤治疗良性前列腺增生症的疗效观察", 现代中西医结合杂志, no. 01, pages 377 - 21 *
田文生,林泽银: "中药内服外浴法治疗前列腺增生症63例", no. 04, pages 29 *
韦景春: "前列腺增生症中医药治疗概述", 实用中医内科杂志, no. 01, pages 2 - 5 *

Also Published As

Publication number Publication date
CN114832052B (en) 2023-09-05

Similar Documents

Publication Publication Date Title
CN102205026B (en) Chinese medicinal composition for treating children chronic sinusitis and preparation method thereof
CN103623188B (en) A kind of Traditional Chinese medicine cataplasma for the treatment of knee osteoarthritis and preparation method thereof
CN103263601B (en) Chinese herbal preparation for accelerating fracture post-operation healing and preparation method of Chinese herbal preparation
CN110812438A (en) Traditional Chinese medicine composition for relieving visual fatigue, preparation method and application
CN103705632B (en) The application of BUPIXIAO PIAN in preparation treatment penile induration disease drug
CN114832052A (en) Traditional Chinese medicine composition for treating benign prostatic hyperplasia
CN102772699B (en) Traditional Chinese medicine composition for treating chronic pelvic inflammatory disease
CN103920044A (en) Medicine for treating urethral calculus and preparation method thereof
CN104971271A (en) Medicine for treating benign prostatic hyperplasia due to damp-retained heat and preparation method thereof
CN106177639A (en) One treats psoriatic Chinese medicine composition and preparation method thereof
CN111214638A (en) Traditional Chinese medicine liniment for treating gout and preparation method thereof
CN110960592A (en) Traditional Chinese medicine composition for treating cholecystitis complicated with cholelithiasis and preparation method thereof
CN104623304A (en) Lotion for treating chronic skin ulcer caused by damp-heat and toxicity accumulation and preparation method of lotion
CN104338052A (en) Formula of traditional Chinese medicine for treating cerebral thrombosis
CN113876889B (en) Traditional Chinese medicine composition for treating premature ejaculation
CN102670858B (en) Lotion for treating inflammatory external hemorrhoids
CN109833371B (en) Traditional Chinese medicine composition for treating constipation after hemorrhoids and fistula operation and preparation method and application thereof
CN105126065A (en) Traditional Chinese medicine composition for treating hyperlipidemia and purpose thereof
CN108114087B (en) Traditional Chinese medicine composition and plaster for preventing and treating cardiovascular and cerebrovascular diseases and preparation method thereof
CN106138399A (en) A kind of Chinese medicine composition treating rheumatoid arthritis and preparation method thereof
CN105412417A (en) Traditional Chinese medicine ointment for treating tenosynovitis and preparation method thereof
CN105687445A (en) Traditional Chinese medicine composition for treating hypochondriac pain and jaundice due to liver and gallbladder damp-heat syndrome
CN105617161A (en) Traditional Chinese medicine composition for treating gout
CN105106776A (en) Medicine used for treating intraperitoneal abscesses in cooperation with operations and preparation method
CN115554333A (en) Prescription of external-use medicine for radically curing piles and its preparation technology

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant